TherapyX Inc. is a privately held early stage biotechnology company engaged in the discovery and development of nanoparticulate immune therapeutics to treat cancer, infectious disease and autoimmune disorders.

Overview

TherapyX, Inc. is advancing the development and commercialization of nanoencapsulated immune-modulatory biologics (NanoCapTM) for the treatment of autoimmune/inflammatory diseases, cancer and infection. The company’s Phase Inversion Nanoencapsulation (PIN) technology provides a customizable platform for the development of sustained-release nanoparticulate protein formulations.  TherapyX, Inc. has a broad pipeline of products at discovery and pre-clinical stages. Our most advanced preclinical products are TGFβ NanoCapTM and IL12 NanoCapTM. 

Technology Platform

TherapyX Inc. has licensed the exclusive worldwide rights to the patented technology needed to produce sustained-release nanoparticulate protein therapeutics. The PIN technology represents a breakthrough in encapsulation of biological macromolecules for parenteral and oral delivery. In addition to maintaining full biological activity of the macromolecule, the process produces a drug product that sustains physiological levels of the therapeutic in the disease microenvironment and is shelf stable at room temperature. This unique formulation provides a significant advantage for TherapyX, Inc. over other competing generic biologics. The company is utilizing the PIN platform to expand its protein-based product pipeline via generation of human-like therapeutics with selective and predictable activity.